Rinzimetostat (TFA)
Rinzimetostat (ORIC-944) TFA is the TFA salt form of ORIC. Rinzimetostat TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). Rinzimetostat TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer[1][2].
Product Specifications
Product Name Alternative
ORIC-944 (TFA)
UNSPSC
12352005
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/oric-944-tfa.html
Purity
98.87
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC1=C(C=CC(CN(C)C)=C1)C2=CN=C(N3C=C(N=C23)C#N)NCC4=C(C=CC5=C4CCO5)F.O=C(C(F)(F)F)O
Molecular Formula
C28H26F4N6O3
Molecular Weight
570.54
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD106 / VCAM1 (1.4C3), CF740 conjugate, 0.1mg/mL
Ep-CAM / CD326 (VU-1D9), CF405S conjugate, 0.1mg/mL
